A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib


Dasatinib, chylothorax, chronic myeloid leukaemia


Dasatanib is a second-generation tyrosine kinase inhibitor with activity on the BCR-ABL fusion gene. it is used in the treatment of BCR-ABL positive chronic myeloid leukaemia and has the known side effect of pleural effusion. This usually involves exudate with the presence of lymphocytes. A more common side effect is the development of chylothorax. We describe a case of a 67-years-old man with chronic myeloid leukaemia, for which treatment with dasatinib, with the presence of a right-sided chylothorax. The man presented at an outpatient consultation due to complaints for exertional dyspnoea. Radiographic imaging showed the presence of right-sided pleural effusion. Several punctures were performed with an evacuation of 4,900 mL bloody chylous fluid in total. Each puncture revealed an increased concentration of triglycerides on the fluid, hence confirming a recurring chylothorax. A pleurodesis was performed as a final therapy. Bosutinib was substituted for dasatinib eight months prior to initial admission, making this the first reported persisting dasatinib-induced chylothorax after discontinuation. 



  • Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med. 2010;16(4):351–6.
  • Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34(20):2333–40.
  • Hsu CC, Hsu JF, Wu KL. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review. Respirol Case Rep. 2021;9(6):1–5.
  • Chen B, Wu Z, Wang Q, Li W, Cheng D. Dasatinib-induced chylothorax: report of a case and review of the literature. Invest New Drugs. 2020;38(5):1627–32.
  • Al-abcha A, Iftikhar MH, Rous FA, Laird-Fick H. Chylothorax: Complication attributed to dasatinib use. BMJ Case Rep. 2019;12(12):10–2.
  • Doerr CH, Allen MS, Nichols FC 3rd, Ryu JH. Etiology of chylothorax in 203 patients. Mayo Clin Proc. 2005 Jul;80(7):867-70. doi: 10.4065/80.7.867. PMID: 16007891.
  • Phan C, Jutant E-M, Tu L, Thuillet R, Seferian A, Montani D, et al. Dasatinib increases endothelial permeability leading to pleural effusion. Eur Respir J. 2018;51(1):1–14.
  • Published: 2022-10-17

    Issue: 2022: Vol 9 No 10 (view)

    Section: Articles

    How to cite:
    Bradt N, Olbrechts F, Alexander P, Salembier A. A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib. EJCRIM 2022;9 doi:10.12890/2022_003601.